Kirsten M Selnæs1,2, Brage Krüger-Stokke3,4, Mattijs Elschot3, Frode Willoch5, Øystein Størkersen6, Elise Sandsmark3, Siver A Moestue3, May-Britt Tessem3, Dag Halvorsen7, Eirik Kjøbli7, Anders Angelsen8, Sverre Langørgen4, Helena Bertilsson7,9, Tone F Bathen3. 1. Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Post box 8905, MTFS, 7491, Trondheim, Norway. kirsten.m.selnas@ntnu.no. 2. Department of Radiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. kirsten.m.selnas@ntnu.no. 3. Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Post box 8905, MTFS, 7491, Trondheim, Norway. 4. Department of Radiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 5. Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway. 6. Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 7. Department of Urology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 8. Urologiklinikken AS, Nøtterøy, Norway. 9. Department of Cancer Research and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
Abstract
OBJECTIVE: To investigate the diagnostic potential of simultaneous 18F-fluciclovine PET/MRI for pelvic lymph node (LN) staging in patients with high-risk prostate cancer. METHODS: High-risk prostate cancer patients (n=28) underwent simultaneous 18F-fluciclovine PET/MRI prior to surgery. LNs were removed according to a predefined template of eight regions. PET and MR images were evaluated for presence of LN metastases according to these regions. Sensitivity/specificity for detection of LN metastases were calculated on patient and region basis. Sizes of LN metastases in regions with positive and negative imaging findings were compared with linear mixed models. Clinical parameters of PET-positive and -negative stage N1 patients were compared with the Mann-Whitney U test. RESULTS: Patient- and region-based sensitivity/specificity for detection of pelvic LN metastases was 40 %/87.5 % and 35 %/95.7 %, respectively, for MRI and 40 %/100 % and 30 %/100 %, respectively, for PET. LN metastases in true-positive regions were significantly larger than metastases in false-negative regions. PET-positive stage N1 patients had higher metastatic burden than PET-negative N1 patients. CONCLUSION: Simultaneous 18F-fluciclovine PET/MRI provides high specificity but low sensitivity for detection of LN metastases in high-risk prostate cancer patients. 18F-Fluciclovine PET/MRI scan positive for LN metastases indicates higher metastatic burden than negative scan. KEY POINTS: • 18F-Fluciclovine PET/MRI has high specificity for detection of lymph node metastasis. • 18F-Fluciclovine PET/MRI lacks sensitivity to replace ePLND. • 18F-Fluciclovine PET/MRI may be used to aid surgery and select adjuvant therapy. • 18F-Fluciclovine PET-positive patients have more extensive disease than PET-negative patients. • Size of metastatic lymph nodes is an important factor for detection.
OBJECTIVE: To investigate the diagnostic potential of simultaneous 18F-fluciclovine PET/MRI for pelvic lymph node (LN) staging in patients with high-risk prostate cancer. METHODS: High-risk prostate cancerpatients (n=28) underwent simultaneous 18F-fluciclovine PET/MRI prior to surgery. LNs were removed according to a predefined template of eight regions. PET and MR images were evaluated for presence of LN metastases according to these regions. Sensitivity/specificity for detection of LN metastases were calculated on patient and region basis. Sizes of LN metastases in regions with positive and negative imaging findings were compared with linear mixed models. Clinical parameters of PET-positive and -negative stage N1 patients were compared with the Mann-Whitney U test. RESULTS:Patient- and region-based sensitivity/specificity for detection of pelvic LN metastases was 40 %/87.5 % and 35 %/95.7 %, respectively, for MRI and 40 %/100 % and 30 %/100 %, respectively, for PET. LN metastases in true-positive regions were significantly larger than metastases in false-negative regions. PET-positive stage N1 patients had higher metastatic burden than PET-negative N1 patients. CONCLUSION: Simultaneous 18F-fluciclovine PET/MRI provides high specificity but low sensitivity for detection of LN metastases in high-risk prostate cancerpatients. 18F-Fluciclovine PET/MRI scan positive for LN metastases indicates higher metastatic burden than negative scan. KEY POINTS: • 18F-Fluciclovine PET/MRI has high specificity for detection of lymph node metastasis. • 18F-Fluciclovine PET/MRI lacks sensitivity to replace ePLND. • 18F-Fluciclovine PET/MRI may be used to aid surgery and select adjuvant therapy. • 18F-Fluciclovine PET-positive patients have more extensive disease than PET-negative patients. • Size of metastatic lymph nodes is an important factor for detection.
Entities:
Keywords:
Adenocarcinoma; FACBC; Magnetic resonance imaging; N-staging; Positron-emission tomography
Authors: David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: Alberto Briganti; Felix K-H Chun; Andrea Salonia; Nazareno Suardi; Andrea Gallina; Luigi Filippo Da Pozzo; Marco Roscigno; Giuseppe Zanni; Luc Valiquette; Patrizio Rigatti; Francesco Montorsi; Pierre I Karakiewicz Journal: Eur Urol Date: 2006-08-31 Impact factor: 20.096
Authors: Sandeep Sankineni; Anna M Brown; Michele Fascelli; Yan Mee Law; Peter A Pinto; Peter L Choyke; Baris Turkbey Journal: Curr Urol Rep Date: 2015-05 Impact factor: 3.092
Authors: Baris Turkbey; Esther Mena; Joanna Shih; Peter A Pinto; Maria J Merino; Maria L Lindenberg; Marcelino Bernardo; Yolanda L McKinney; Stephen Adler; Rikard Owenius; Peter L Choyke; Karen A Kurdziel Journal: Radiology Date: 2013-11-08 Impact factor: 11.105
Authors: Georgios Gakis; Stephen A Boorjian; Alberto Briganti; Steven Joniau; Guram Karazanashvili; R Jeffrey Karnes; Agostino Mattei; Shahrokh F Shariat; Arnulf Stenzl; Manfred Wirth; Christian G Stief Journal: Eur Urol Date: 2013-05-22 Impact factor: 20.096
Authors: Karen Lyons; Victor Seghers; James I L Sorensen; Wei Zhang; Michael J Paldino; Rajesh Krishnamurthy; Eric M Rohren Journal: AJR Am J Roentgenol Date: 2015-11 Impact factor: 3.959
Authors: Baris Turkbey; Marcin Czarniecki; Joanna H Shih; Stephanie A Harmon; Piyush K Agarwal; Andrea B Apolo; Deborah E Citrin; James L Gulley; Mukesh Harisinghani; Ravi A Madan; Adam R Metwalli; Edmond Paquette; Peter A Pinto; Soroush Rais-Bahrami; Lindsay S Rowe; Bradford J Wood; Paula M Jacobs; Liza Lindenberg; William Dahut; Peter L Choyke Journal: AJR Am J Roentgenol Date: 2019-10-15 Impact factor: 3.959
Authors: Mehrdad Alemozaffar; Akinyemi A Akintayo; Olayinka A Abiodun-Ojo; Dattatraya Patil; Faisal Saeed; Yijian Huang; Adeboye O Osunkoya; Mark M Goodman; Martin Sanda; David M Schuster Journal: J Urol Date: 2020-04-29 Impact factor: 7.450
Authors: Barbara J Amorim; Vinay Prabhu; Sara S Marco; Debra Gervais; Willian E Palmer; Pedram Heidari; Mark Vangel; Philip J Saylor; Onofrio A Catalano Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-06 Impact factor: 9.236
Authors: Olayinka A Abiodun-Ojo; Akinyemi A Akintayo; Gabriel L Sica; Mehrdad Alemozaffar; David M Schuster Journal: Clin Nucl Med Date: 2020-12 Impact factor: 10.782
Authors: Morteza Esmaeili; Nassim Tayari; Tom Scheenen; Mattijs Elschot; Elise Sandsmark; Helena Bertilsson; Arend Heerschap; Kirsten M Selnæs; Tone F Bathen Journal: Front Oncol Date: 2018-11-15 Impact factor: 6.244
Authors: Jad S Husseini; Bárbara Juarez Amorim; Angel Torrado-Carvajal; Vinay Prabhu; David Groshar; Lale Umutlu; Ken Herrmann; Lina García Cañamaque; José Ramón García Garzón; William E Palmer; Pedram Heidari; Tiffany Ting-Fang Shih; Jacob Sosna; Cristina Matushita; Juliano Cerci; Marcelo Queiroz; Valdair Francisco Muglia; Marcello H Nogueira-Barbosa; Ronald J H Borra; Thomas C Kwee; Andor W J M Glaudemans; Laura Evangelista; Marco Salvatore; Alberto Cuocolo; Andrea Soricelli; Christian Herold; Andrea Laghi; Marius Mayerhoefer; Umar Mahmood; Ciprian Catana; Heike E Daldrup-Link; Bruce Rosen; Onofrio A Catalano Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-22 Impact factor: 9.236